Forward Looking Statement

This presentation contains forward-looking statements & estimates made by the management of the Company with respect to the anticipated future performance of MDxHealth & the market in which it operates. Such statements & estimates are based on various assumptions & assessments of known & unknown risks, uncertainties & other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict & may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of MDxHealth, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements & estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements & estimates. MDxHealth disclaims any obligation to update any such forward-looking statement or estimates to reflect any change in the Company’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement or estimate is based, except to the extent required by Belgian law.

Analyst Coverage

Any opinions, estimates or forecasts made by analysts are theirs alone and do not represent opinions, forecasts or predictions of MDxHealth or its management. Requests for copies of analyst reports should be directed at the respective analyst & institution.
Prostate & Bladder Cancer Incidence
North America & Europe

709,134
New cases of prostate cancer

242,273
New cases of bladder cancer

Annual Numbers
North America
84,062
288,235
Europe
158,211
420,899

1. GLOBOCAN 2012 (IARC) Population forecasts were extracted from the United Nations, World Population prospects, the 2012 revision. Numbers are computed using age-specific rates and corresponding populations for 10 age-groups.
Prostate Cancer by Numbers
EU and US

1 in 6
Men will develop prostate cancer

2 million
Biopsies performed
Prostate Cancer Challenges

Unmet Clinical Needs

- 5 million abnormal PSA results
- 1.3 million biopsies
- 180,000 diagnosed w/cancer
- ~1 million neg biopsies
- 27,540 deaths

Who needs initial biopsy?

Who needs repeat biopsy?

Who needs treatment?

Select MDx for Prostate Cancer

Confirm MDx for Prostate Cancer

Inform MDx for Prostate Cancer

Aubry W et al; American Health Drug and Benefits 2013.6(1): 15-24
Prostate cancer is the 2nd most common cancer diagnosed in men globally\(^1\) with over 2M biopsies conducted annually in the US & Europe\(^2,3\)

---

Early Detection is Key

5 years after being diagnosed with prostate cancer, 99% of men are alive.

But only 28% of men with advanced disease.
SelectMDx for Prostate Cancer

Unmet Clinical Need

5 Million men with elevated PSA

Only 25% at risk for High Grade Prostate Cancer
Valuable liquid biopsy test for patients and physicians
Available as LDT and IVD product

The Product
• Non-Invasive urine test
• RNA PCR test

The Urologist
• Part of routine examination
• Identifies patient for MRI or biopsy

The Patient
• Non-invasive sample collection
• Easy to explain
SelectMDx for Prostate Cancer
Non-invasive, Liquid Biopsy to Identify Patients for Prostate Biopsy

Urine test for the prediction of histopathological outcome of prostate biopsy
Clinical Utility Old and New generation Urine PCa Tests

Area Under an ROC Curve

SelectMDx

AUC 0.90

PCA3

AUC 0.68

Avoiding biopsies

98%

NPV for high grade prostate cancer

PCA3

36%

SelectMDx

53%
SelectMDx Guides Patient Selection for mpMRI

PIRAD score is radiologist’s Gleason score; PIRAD 4-5 indication for biopsy

Retrospective multi-center study
- The median SelectMDx risk score was significantly higher in patients who had a suspicious lesion on MRI (p<0.001)
- Outcome: SelectMDx correlates with PIRAD 4-5

Prospective multicenter study 4M (Prof. Barentsz PI)
- Recruitment completed Q1 207 (600)
- Expected outcome; SelectMDx correlates with PIRAD 4-5
Unmet Diagnostic Need for Better Diagnostic Products

1.3 Million biopsies

15% PCa Diagnosis
25% False negative results
18% Complications

Aubry W et al; American Health Drug and Benefits 2013.6(1): 15-24
American Cancer Society 2016
Valuable Tissue Biopsy test for physicians and payors

The Product
• Proprietary tissue biopsy PCR DNA test
• NPV 96% for high grade PCa

The Urologist
• Provides actionable information
• In the NCCN guidelines

The Patient
• Avoiding unnecessary repeat biopsies
• Using leftover tissue

Avoiding Unnecessary repeat Biopsies
ConfirmMDx for Prostate Cancer

Tissue Biopsy to forgo a repeat biopsy

Pathology

Initial biopsy negative

DNA Tissue Test

Residual biopsy

Result

Likely hood risk score

Follow-up

Discuss with patient

MRi or Biopsy

routine PSA
Clinical Performance ConfirmMDx
ConfirmMDx for Prostate

Odds Ratio for GS ≥ 7 PCa

1.0  1.5  2.3  2.4
Age  % + Biopsies PSA Atypia ConfirmMDx Risk Profile

15.8

Clinical Risk Factors

96% NPV for high grade prostate cancer

Risk Score Predicts High-Grade Prostate Cancer in DNA-Methylation Positive, Histopathologically Negative Biopsies

Leander Van Neste,1 Alan W. Partin,2 Grant D. Stewart,3 Jonathan I. Epstein,2 David J. Harrison,4 and Wim Van Creickinge*1

Van Neste et al. The Prostate (2016)
Clinical application of MDxhealth biomarker tests
Success of SelectMDx and ConfirmMDx since Launch

SelectMDx for Prostate Cancer

>10,000 tests completed
Since launch May 2016

ConfirmMDx for Prostate Cancer

>65,000 tests completed
Since launch May 2012
A Global Billion Dollar Market for SelectMDx and ConfirmMDx

10 M
SelectMDx

+ 

1.1 M
ConfirmMDx

> $5B
Addressable market
Successful Global Commercial Strategy
US & ROW

Patients

- Forgo unnecessary procedures
- > 75,000 patients tested

Physicians

- Providing actionable information
- ~ 4,000 have ordered a MDxH test

Visibility

- Strong brand & market validation
- > 60 scientific publications

Credibility

- Covered by CMS, VA, Kaiser
- NCCN Guidelines
Increasing Coverage of ConfirmMDx

Covered Lives (millions)

- Medicare Coverage
- NCCN Inclusion

2013 2014 2015 2016 2017

- Kaiser Permanente
- VA
- U.S. Department of Veterans Affairs
- HIGHMARK, Blue Cross Blue Shield
- MultiPlan
- Independence
- Horizon
- Pacific Health Alliance
- BlueCross BlueShield of Illinois
- AmeriHealth New Jersey
- BlueCross BlueShield of Montana
- ACPN
- PMCS
- Fortified Provider Network
- PRIME Health Services, Inc.
- Priority Health
- The HealthPlan
- Medicare
- FedMed

©2017 All rights reserved
68% of the “At Risk” Prostate Biopsy Patients are Covered for ConfirmMDx
Product Compliance Key for MDxHealth Success

Regulatory & Quality

CLIA Lab US

Service Lab EU

Confirm MDx for Prostate Cancer

Select MDx for Prostate Cancer

Assure MDx for Bladder Cancer

Select MDx for Prostate Cancer

ISO 13485:2016

CE
MDxHealth Bladder Cancer Portfolio Opportunity
Objective: establish MDxHealth as market leader in molecular diagnostics for urologic oncology


Who should be referred to Urology?
~18M Hematuria Patients

Who gets cystoscopy?
~1.8M Patients Referred to Urology

Who has bladder cancer?
~630K Cystoscopy Procedures

How to treat?
~80K Bladder Cancers

Who will recur?
~300K Monitoring
Bladder Cancer Diagnosis

Standard of Care

Bladder cancer is the most expensive cancer to treat

US Bladder Cancer Market Expands our opportunity by $500M

18 Million Hematuria cases

630K Cystoscopies procedures

20K Missed Diagnosis

230K Unnecessary Cystoscopies


*Calculation based on 70% of NIH bladder cancer incidence
Valuable Liquid Biopsy test for Physicians and Patients

MDxHealth Second liquid biopsy test

- Proprietary (epi)genetic qPCR test
- Non-invasive urine test

- Provides actionable information
- Recommends cystoscopy or CT scan

- Avoiding unnecessary cystoscopies
- Only requires a urine sample

Avoiding Unnecessary Cystoscopies
AssureMDx for Bladder Cancer

Non-invasive, Liquid Biopsy to Identify Patients with Bladder Cancer

Patient

Urine Test

Runs on any open PCR/Sequence instrument

Result

Likelihood risk score

Follow-up

Yes/No CT scan or Cystoscopy

Routine monitoring
Clinical Performance AssureMDx
AssureMDx for Prostate

AssureMDx performance at different stage of Bladder Cancer

<table>
<thead>
<tr>
<th>Tumor Stage</th>
<th>NPV*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ta</td>
<td>99.3%</td>
</tr>
<tr>
<td>T1</td>
<td>99.5%</td>
</tr>
<tr>
<td>T2-T4</td>
<td>99.6%</td>
</tr>
<tr>
<td>Low Grade (G1&amp;G2)</td>
<td>99.2%</td>
</tr>
<tr>
<td>High Grade (G3)</td>
<td>99.6%</td>
</tr>
</tbody>
</table>

Sensitivity

- Cytology: 43%
- FISH: 76%
- AssureMDx: 93%
PredictMDx for Glioblastoma

**MGMT**

- LDT test for Brain cancer
- Proprietary tissue biopsy PCR DNA test

- Test required for newly diagnosed stage IV Glioma
- Included in the NCCN guidelines

- Licensed to LabCorp for North America
- Contracted with Histogenex in Europe

Tissue Test
Our success is translating into financial growth

Full Year 2016

24K patients tested

70% revenue increase

$30.9M cash & equivalents

$2.5M EBITDA improvement
2017 Outlook

- 55-75% growth on product and service income
- Continued reduction in operating losses
- Improved collectability & reduced working capital requirements
- Increased private US payor adoption & favourable reimbursement rates